deltatrials
Unknown PHASE4 NCT00220714

PREvent First Episode Relapse (PREFER)

Effectiveness of Long-Acting Risperidone in the Maintenance Treatment of First-Episode Schizophrenia

Sponsor: Janssen, LP

Conditions Schizophrenia
Interventions Family Psychoeducation atypical antipsychotics:oral vs. long-acting route
Updated 5 times since 2017 Last updated: Mar 28, 2008 Started: Nov 30, 2004 Completion: Dec 31, 2007

A PHASE4 clinical study on Schizophrenia, this trial is ongoing. The trial is conducted by Janssen, LP and has accumulated 5 data snapshots since 2004. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE4

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE4

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE4

    First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen, LP
  • State University of New York - Downstate Medical Center
Data source: State University of New York - Downstate Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Brooklyn, United States